1 active not recruiting, 1 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Recruiting 1 |
Follow LMD: new trials by email Literature Review of LMD trials Research Report on LMD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study Tucatinib 150 MG, Trastuzumab, Capecitabine - HER2-positive Breast Cancer, LMD | Phase 2 | Recruiting | Sunnybrook Health Sciences Centre | 30 | 2023-11-25 | 2026-02-23 |
| Study Assessing QBS72S For Treating Brain Metastases QBS72S - Brain Metastases, Breast Cancer | Phase 2 | Active not recruiting | Melanie Hayden Gephart | 21 | 2022-08-16 | 2026-10-20 |
Breast Neoplasms (2) · Meningeal Neoplasms (2) · Brain Neoplasms (1) · Lung Neoplasms (1)
Breast Diseases (2) · Central Nervous System Neoplasms (2) · Neoplasms (2) · Neoplasms by Site (2) · Nervous System Diseases (2) · Nervous System Neoplasms (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2) · Brain Diseases (1) · Central Nervous System Diseases (1) · Lung Diseases (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1) · Thoracic Neoplasms (1)
Capecitabine (1) · Trastuzumab (1) · tucatinib (1)
Melanie Hayden Gephart (1) · Sunnybrook Health Sciences Centre (1)
Canada (1) · United States (1)